TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Based on these encouraging results, the global phase III ECHELON-2 study was performed, in which newly diagnosed patients with CD30-positive PTCL were randomized to receive brentuximab vedotin plus CHP or CHOP [82].